Verrica Pharmaceuticals (VRCA) Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315

Go back to Verrica Pharmaceuticals (VRCA) Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315
(NASDAQ: VRCA) Delayed: 5.65 +0.01 (0.18%)
Previous Close $5.64    52 Week High
Open $5.46    52 Week Low
Day High $5.92    P/E N/A 
Day Low $5.30    EPS
Volume 34,302